01:37 PM EDT, 09/23/2024 (MT Newswires) -- VistaGen Therapeutics ( VTGN ) said Monday it has started enrollment for its phase 3 trial of its nasal spray fasedienol for the treatment of social anxiety disorder.

Fasedienol aims to provide an acute treatment option for social anxiety disorder by targeting nose-to-brain neurocircuitry, the company said.

Price: 3.10, Change: -0.05, Percent Change: -1.59